SIBO and SIFO: Small Intestinal Bacterial and Fungal Overgrowth

Treating SIBO without addressing what's allowing the overgrowth produces a cycle of recurrence. The question isn't only what organisms are there — it's what's letting them establish in the first place.

What patients tell us

“I bloat after every meal. I react to foods I used to tolerate. I've been told I have IBS, and standard treatments haven't helped. I tried rifaximin once and felt better briefly, but it came back. Now I'm wondering if there's something else going on or whether I'll just keep cycling through this.”

What SIBO and SIFO are

The small intestine is normally a relatively sparse microbial environment — bacterial populations in the upper GI tract should be much lower than those in the colon. Several mechanisms maintain this gradient: gastric acid kills incoming organisms, the migrating motor complex sweeps the small intestine clean between meals, the ileocecal valve prevents backflow from the colon, and immunologic surveillance limits microbial overgrowth.

Small intestinal bacterial overgrowth (SIBO) occurs when bacterial populations in the small intestine rise above normal levels, producing symptoms through fermentation of carbohydrates, interference with normal absorption, and immune activation. Small intestinal fungal overgrowth (SIFO) is the parallel condition involving fungal organisms (typically Candida species). The two conditions often coexist — addressing only the bacterial component while leaving the fungal component active produces incomplete response.

SIBO is increasingly recognized in gastroenterology, though the clinical framework varies. Mainstream evaluation uses breath testing, with treatment typically rifaximin alone or combined with neomycin for methane-predominant cases. The recognition that SIFO frequently coexists, and that addressing recurrence requires more than antimicrobial treatment, is less consistently part of mainstream practice.

Why SIBO recurs

The clinical pattern that defines successful versus unsuccessful SIBO treatment is rarely about the initial response to antimicrobials — most patients improve initially. The pattern is whether the improvement holds. Patients who recur within weeks to months haven't been treated for the underlying conditions that allowed the overgrowth to develop in the first place.

Several mechanisms allow SIBO to establish and recur. Impaired migrating motor complex function is one of the most common contributors. Low gastric acid removes one of the body's primary barriers to bacterial entry. Structural issues create environments where organisms establish. Bile acid insufficiency reduces antimicrobial activity. Immune dysfunction at the gut barrier allows organisms to persist. Slow transit from any cause favors overgrowth.

Post-infectious SIBO is a particular pattern worth recognizing. Patients who develop SIBO after acute gastroenteritis often have antibodies to cytolethal distending toxin and vinculin, reflecting the molecular mimicry mechanism by which post-infectious autoimmunity damages the migrating motor complex.

Why SIFO often coexists

The same factors that allow bacterial overgrowth often allow fungal overgrowth. Beyond shared contributors, antibiotic treatment for SIBO can selectively suppress bacterial competitors of fungal organisms, allowing fungal populations to expand. Patients who get partial response to SIBO treatment but continue to have GI symptoms — particularly itching, food sensitivities, brain fog, or fatigue — often have SIFO that's been missed.

Diagnosis of SIFO is harder than diagnosis of SIBO. Breath testing identifies hydrogen and methane producers but not fungi. Specialty stool testing identifies fungal organisms but reflects colonic flora more than small intestinal organisms. Clinical correlation remains essential.

How iHeal evaluates SIBO and SIFO

The evaluation considers both organism identification and the contributors that allowed overgrowth to develop. Breath testing identifies hydrogen, methane, and increasingly hydrogen sulfide producers. Specialty stool testing assesses the broader microbiome and identifies fungal organisms. Serology for post-infectious autoimmunity is considered in patients with the relevant clinical history. The broader evaluation looks at motility, gastric acid status, structural factors, and the 5M picture that may be contributing to gut dysfunction.

Treatment combines organism reduction with addressing the underlying contributors. Antimicrobial selection considers the specific overgrowth pattern. Beyond antimicrobials, treatment includes motility support when relevant, gastric acid support when low acid is contributing, biofilm-disrupting strategies for resistant cases, and rebuilding the gut environment to support healthy microbiome restoration.

Dr. Matthew Everett, MD

Pro Tip · From Dr. Everett

Matthew Everett, MDEnvironmental Medicine · IFMCP

The evaluation considers both organism identification and the contributors that allowed overgrowth to develop. Breath testing identifies hydrogen, methane, and increasingly hydrogen sulfide producers. Specialty stool testing assesses the broader microbiome and identifies fungal organisms. Serology for post-infectious autoimmunity is considered in patients with the relevant clinical history. The broader evaluation looks at motility, gastric acid status, structural factors, and the 5M picture that may be contributing to gut dysfunction.

Sources & Further Reading

Concerned this applies to you?

A consultation is where we figure out whether sibo and sifo is actually contributing to your symptoms — and what to do about it.

On This Page

SIBO and SIFO: Small Intestinal Bacterial and Fungal Overgrowth

Treating SIBO without addressing what's allowing the overgrowth produces a cycle of recurrence. The question isn't only what organisms are there — it's what's letting them establish in the first place.

What patients tell us

“I bloat after every meal. I react to foods I used to tolerate. I've been told I have IBS, and standard treatments haven't helped. I tried rifaximin once and felt better briefly, but it came back. Now I'm wondering if there's something else going on or whether I'll just keep cycling through this.”

What SIBO and SIFO are

The small intestine is normally a relatively sparse microbial environment — bacterial populations in the upper GI tract should be much lower than those in the colon. Several mechanisms maintain this gradient: gastric acid kills incoming organisms, the migrating motor complex sweeps the small intestine clean between meals, the ileocecal valve prevents backflow from the colon, and immunologic surveillance limits microbial overgrowth.

Small intestinal bacterial overgrowth (SIBO) occurs when bacterial populations in the small intestine rise above normal levels, producing symptoms through fermentation of carbohydrates, interference with normal absorption, and immune activation. Small intestinal fungal overgrowth (SIFO) is the parallel condition involving fungal organisms (typically Candida species). The two conditions often coexist — addressing only the bacterial component while leaving the fungal component active produces incomplete response.

SIBO is increasingly recognized in gastroenterology, though the clinical framework varies. Mainstream evaluation uses breath testing, with treatment typically rifaximin alone or combined with neomycin for methane-predominant cases. The recognition that SIFO frequently coexists, and that addressing recurrence requires more than antimicrobial treatment, is less consistently part of mainstream practice.

Why SIBO recurs

The clinical pattern that defines successful versus unsuccessful SIBO treatment is rarely about the initial response to antimicrobials — most patients improve initially. The pattern is whether the improvement holds. Patients who recur within weeks to months haven't been treated for the underlying conditions that allowed the overgrowth to develop in the first place.

Several mechanisms allow SIBO to establish and recur. Impaired migrating motor complex function is one of the most common contributors. Low gastric acid removes one of the body's primary barriers to bacterial entry. Structural issues create environments where organisms establish. Bile acid insufficiency reduces antimicrobial activity. Immune dysfunction at the gut barrier allows organisms to persist. Slow transit from any cause favors overgrowth.

Post-infectious SIBO is a particular pattern worth recognizing. Patients who develop SIBO after acute gastroenteritis often have antibodies to cytolethal distending toxin and vinculin, reflecting the molecular mimicry mechanism by which post-infectious autoimmunity damages the migrating motor complex.

Why SIFO often coexists

The same factors that allow bacterial overgrowth often allow fungal overgrowth. Beyond shared contributors, antibiotic treatment for SIBO can selectively suppress bacterial competitors of fungal organisms, allowing fungal populations to expand. Patients who get partial response to SIBO treatment but continue to have GI symptoms — particularly itching, food sensitivities, brain fog, or fatigue — often have SIFO that's been missed.

Diagnosis of SIFO is harder than diagnosis of SIBO. Breath testing identifies hydrogen and methane producers but not fungi. Specialty stool testing identifies fungal organisms but reflects colonic flora more than small intestinal organisms. Clinical correlation remains essential.

How iHeal evaluates SIBO and SIFO

The evaluation considers both organism identification and the contributors that allowed overgrowth to develop. Breath testing identifies hydrogen, methane, and increasingly hydrogen sulfide producers. Specialty stool testing assesses the broader microbiome and identifies fungal organisms. Serology for post-infectious autoimmunity is considered in patients with the relevant clinical history. The broader evaluation looks at motility, gastric acid status, structural factors, and the 5M picture that may be contributing to gut dysfunction.

Treatment combines organism reduction with addressing the underlying contributors. Antimicrobial selection considers the specific overgrowth pattern. Beyond antimicrobials, treatment includes motility support when relevant, gastric acid support when low acid is contributing, biofilm-disrupting strategies for resistant cases, and rebuilding the gut environment to support healthy microbiome restoration.

Dr. Matthew Everett, MD

Pro Tip · From Dr. Everett

Matthew Everett, MDEnvironmental Medicine · IFMCP

The evaluation considers both organism identification and the contributors that allowed overgrowth to develop. Breath testing identifies hydrogen, methane, and increasingly hydrogen sulfide producers. Specialty stool testing assesses the broader microbiome and identifies fungal organisms. Serology for post-infectious autoimmunity is considered in patients with the relevant clinical history. The broader evaluation looks at motility, gastric acid status, structural factors, and the 5M picture that may be contributing to gut dysfunction.

Sources & Further Reading

Concerned this applies to you?

A consultation is where we figure out whether sibo and sifo is actually contributing to your symptoms — and what to do about it.

On This Page